ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates ZYNLONTA ® (loncastuximab tesirine-lpyl) net sales of $17.0 million in the fourth quarter of ...

ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates ...

Welcome to the ADC Therapeutics Fourth Quarter and Year End 2021 Financial Results Conference Call. My name is Josh and I will be your operator for today's call. At this time, all participants are in ...

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted ...

Detailed price information for Adc Therapeutics Sa (ADCT-N) from The Globe and Mail including charting and trades.

Amid a wave of leadership transitions in biopharma, ADC Therapeutics is the latest drugmaker to shake up its management. On Monday, the company said co-founder Chris Martin is stepping back from his ...

The concept of an antibody drug conjugate is straightforward enough: a cancer-killing drug payload attached to a targeting antibody that directs the molecule to cancer cells. Though these targeted ...